Biological approaches to ischemic tissue repair: Gene- and cell-based strategies

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 653-668

  Roncalli, Jerome ^a   Tongers, Jörn ^a   Renault, Marie Ange ^a   Losordo, Douglas W ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Cardivascular disease; Cell therapy; Cerebrovascular disease; Coronary artery disease; Gene therapy; Growth factor; Ischemia; Ischemic stroke; Neovascularization; Peripheral artery disease; Vasculogenesis

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLASMID DNA; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSCRIPTION FACTOR E2F; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENIC GENE THERAPY; BONE MARROW TRANSPLANTATION; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL HOMING; CELL REGENERATION; CELL THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENGRAFTMENT; EVIDENCE BASED MEDICINE; EXERCISE TEST; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INTRACORONARY INFUSION; LIMB ISCHEMIA; LOW DRUG DOSE; NEURAL STEM CELL; NONHUMAN; PATIENT SAFETY; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VIRAL GENE THERAPY; ANIMAL; BIOLOGICAL THERAPY; DISEASE MODEL; FEMALE; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL THERAPY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TISSUE THERAPY; TREATMENT OUTCOME;

EID: 47149110860     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.653     Document Type: Review

References (132)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064), 1498-1504 (1997).
2. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), E69-E171 (2007).
3. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286(11), 1317-1324 (200 1).
4. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. 9(6), 694-701 (2003).
5. Isner JM. Myocardial gene therapy. Nature 415(10), 234-239 (2002).
6. Kastrup J. Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy? Curr. Gene Ther. 3(3), 197-206 (2003).
7. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol. Ther. 15(7), 1233-1247 (2007).
8. Vincent KA, Jiang C, Boltje I, Kelly RA. Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther. 14(10), 781-789 (2007).
9. Stewart DJ, Hilton JD, Arnold JM et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a Phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 13(21), 1503-1511 (2006).
10. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97(12), 1114-1123 (1998).
11. Isner JM, Baumgartner I, Rauh G et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. 28(6), 964-973; discussion 973-975 (1998).
12. Losordo DW, Vale PR, Symes JF et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98(25), 2800-2804 (1998).
13. Vale PR, Losordo DW, Milliken CE et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102(9), 965-974 (2000).
14. Vale PR, Losordo DW, Milliken CE et al. Randomized, single-blind, placebo-controlled pilot study of catheter- based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103(17), 2138-2143 (2001).
15. Kastrup, J, Jorgensen E, Ruck A et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 45(7), 982-988 (2005).
16. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107(10), 1359-1365 (2003).
17. Grines CL, Watkins MW, Helmer G et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105(11), 1291-1297 (2002).
18. Grines CL, Watkins MW, Mahmarian JJ et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42(8), 1339-1347 (2003).
19. Henry TD, Grines CL, Watkins MW et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50(11), 1038-1046 (2007).
20. Nikol S, Baumgartner I, Van Belle E et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 16(5), 972-978 (2008).
21. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 287(5785), 795-801 (1980).
22. Goodrich LV, Scott MP. Hedgehog and patched in neural development and disease. Neuron 21(6), 1243-1257 (1998).
23. Johnson RL, Tabin CJ. Molecular models for vertebrate limb development. Cell 90(6), 979-990 (1997).
24. Pepicelli CV. Lewis PM, McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr. Biol. 8(19), 1083-1086 (1998).
25. Ramalho-Santos M, Melton DA, McMahon AP. Hedgehog signals regulate multiple aspects of gastrointestinal development. Development 127(12), 2763-2772 (2000).
26. Roelink H, Augsburger A, Heemskerk J et al. Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. Cell 76(4), 761-775 (1994).
27. St-Jacques B, Dassule HR, Karavanova I et al. Sonic hedgehog signaling is essential for hair development. Curr. Biol. 8(19), 1058-1068 (1998).
28. St-Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13(16), 2072-2086 (1999).
29. Xu L, Badolato R, Murphy WJ et al. A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 155(3), 1184-1190 (1995).
30. Pola R, Ling LE, Silver M et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7(6), 706-711 (2001).
31. Kusano KF, Pola R, Murayama T et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat. Med. 11 (11), 1197-1204 (2005).
32. Heistad DD, Faraci FM. Gene therapy for cerebral vascular disease. Stroke 27(9), 1688-1693 (1996).
33. Ooboshi H, Welsh MJ, Rios CD, Davidson BL, Heistad DD. Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue. Circ. Res. 77, 7-13 (1995).
34. Rios CD, Ooboshi H, Piegors D, Davidson BL, Heistad DD. Adenovirus-mediated gene transfer to normal and atherosclerotic arteries. A novel approach. Arterioscler. Throm. Vasc. Biol. 15, 2241-2245 (1995).
35. Shimamura M, Sato N, Waguri S et al. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension 47(4), 742-751 (2006).
36. Yoshimura S, Morishita R, Hayashi K et al. Gene transfer of hepatocyte growth factor to subarachnoid space in cerebral hypoperfusion model. Hypertension 39(5), 1028-1034 (2002).
37. Toyoda K, Faraci FM, Watanabe Y et al. Gene transfer of calcitonin gene-related peptide prevents vasoconstriction after subarachnoid hemorrhage. Circ. Res. 87(9), 818-824 (2000).
38. Satoh M, Perkins E, Kimura H et al, Posttreatment with adenovirus-mediated gene transfer of calcitonin gene-related peptide to reverse cerebral vasospasm in dogs. J. Neurosurg. 97(1), 136-142 (2002).
39. Stoodley M, Weihl CC, Zhang ZD et al. Effect of adenovirus-mediated nitric oxide synthase gene transfer on vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 46(5), 1193-1202; discussion 1202-1203 (2000).
40. van Praag H, Schinder AF, Christie BR et al. Functional neurogenesis in the adult hippocampus. Nature 415(6875), 1030-1034 (2002).
41. Yarasheski KE, Campbell JA, Smith K et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am. J. Physiol. 262(3 Pt 1), E261-E267 (1992).
42. Cao L, Jiao X, Zuzga DS et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 36(8), 827-835 (2004).
43. Shimamura M, Sato N, Oshima K et al. Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 109(3), 424-431 (2004).
44. Liu G, Li D, Pasumarthy MK et al. Nanoparticles of compacted DNA transfect postmitotic cells. J. Biol. Chem. 278(35), 32578-32586 (2003).
45. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997).
46. Barile L, Messina E, Giacomello A, Marban E. Endogenous cardiac stem cells. Prog. Cardiovasc. Dis. 50(1), 31-48 (2007).
47. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6), 763-776 (2003).
48. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95(4), 343-353 (2004).
49. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler. Thromb. Vasc. Biol. 23(7), 1185-1189 (2003).
50. Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105(11), 1527-1536 (2000).
51. Aicher A, Rentsch M, Sasaki K et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Cirr. Res. 100(4), 581-589 (2007).
52. Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 97(7), 3422-3427 (2000).
53. Kocher AA. Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7(4), 430-436 (2001).
54. Masuda H, Kalka C, Takahashi T et al. Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ. Res. 101(6), 598-606 (2007).
55. Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5(4), 434-438 (1999).
56. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18(14), 3964-3972 (1999).
57. Lee SH, Wolf PL, Escudero R et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. 342(9), 626-633 (2000).
58. Askari AT, Unzek S, Popovic ZB et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362(9385), 697-703 (2003).
59. Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10(8), 858-864 (2004).
60. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 α mRNA is selectively induced in rat model of myocardial infarction. Inflammation 25(5), 293-300 (2001).
61. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 103(3), 921-926 (2004).
62. Heissig B, Hattori K, Dias S et al. Recruitment of stem and Progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109(5), 625-637 (2002).
63. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9(11), 1370-1376 (2003).
64. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85(3), 221-228 (1999).
65. Wright DE, Bowman EP. Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J. Exp. Med. 195(9), 1145-1154 (2002).
66. Yamaguchi J, Kusano KF, Masuo O et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107(9), 1322-1328 (2003).
67. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9(6), 702-712 (2003).
68. Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92(2), 362-367 (1998).
69. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 109(21 Suppl. 1), II27-II33 (2004).
70. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 111 (3), 363-368 (2005).
71. Ii M, Nishimura H, Iwakura A et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation 111(9), 1114-1120 (2005).
72. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348(7), 593-600 (2003).
73. + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110(10), 1209-1212 (2004).
74. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89(1), E1-E7 (2001).
75. Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22), 2981-2987 (2005).
76. Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109(2), 220-226 (2004).
77. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103(24), 2885-2890 (2001).
78. Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15), 1913-1918 (2002).
79. Kawamoto A, Iwasaki H, Kusano K et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 114(20), 2163-2169 (2006).
80. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 44(8), 1690-1699 (2004).
81. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1210-1221 (2006).
82. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429), 141-148 (2004).
83. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (Bone Marrow Transfer To Enhance ST-elevation Infarct Regeneration) trial. Circulation 113(10), 1287-1294 (2006).
84. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505), 113-121 (2006).
85. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1199-1209 (2006).
86. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28(6), 766-772 (2007).
87. Abdel-Latif A, Both R, Tleyjeh IM et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med. 167(10), 989-997 (2007).
88. Assmus B, Honold J, Schachinger V et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355(12), 1222-1232 (2006).
89. Perin EC, Dohmann HF, Borojevic R et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107(18), 2294-2302 (2003).
90. + stem cells for intractable angina: a Phase I/IIa. double-blind, randomized controlled trial. Circulation 115(25), 3165-3172 (2007).
91. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360(9331), 427-435 (2002).
92. Lau KK, Chan YH, Yiu KH et al. Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. J. Hum. Hypertens. 21(6), 445-451 (2007).
93. Ghani U, Shuaib A, Salam A et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 36(1), 151-153 (2005).
94. Yip HK, Chang LT, Chang WN et al. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 39(1), 69-74 (2008).
95. Sobrino T, Hurtado O, Moro MA et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 38(10), 2759-2764 (2007).
96. Taguchi A, Matsuyama T, Moriwaki H et al. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation 109(24), 2972-2975 (2004).
97. Hess DC, Abe T, Hill WD et al. Hematopoietic origin of microglial and perivascular cells in brain. Exp. Neurol. 186(2), 134-144 (2004).
98. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 441(7097), 1094-1096 (2006).
99. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat. Med. 10(Suppl.), S42-S50 (2004).
100. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ. Res. 90(3), 284-288 (2002).
101. Hess DC, Hill WD, Martin-Studdard A et al. Bone marrow as a source of endothelial cells and Neu N-expressing cells after stroke. Stroke 33(5), 1362-1368 (2002).
102. +) implantation induces neuroplasticity by enhancing β1 integrin-mediated angiogenesis in chronic stroke rats. J. Neurosci. 26(13), 3444-3453 (2006).
103. Shyu WC, Chen CP, Lin SZ, Lee YJ, Li H. Efficient tracking of non-iron-labeled mesenchymal stem cells with serial MRI in chronic stroke rats. Stroke 38(2), 367-374 (2007).
104. Gertz K, Priller J, Kronenberg G et al. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ. Res. 99(10), 1132-1140 (2006).
105. Minger SL, Ekonomou A, Carta EM et al. Endogenous neurogenesis in the human brain following cerebral infarction. Regen. Med. 2(1), 69-74 (2007).
106. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 57(6), 874-882 (2005).
107. Kondziolka D, Steinberg GK, Wechsler L et al. Neurotransplantation for patients with subcortical motor stroke: a Phase 2 randomized trial. J. Neurosurg. 103(1), 38-45 (2005).
108. Castro RF, Jackson KA, Goodell MA et al. Failure of bone marrow cells to transdifferentiate into neural cells in vivo. Science 297(5585), 1299 (2002).
109. Borlongan CV, Skinner SJ, Geaney M et al. Intracerebral transplantation of porcine choroid plexus provides structural and functional neuroprotection in a rodent model of stroke. Stroke 35(9), 2206-2210 (2004).
110. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med. 8(9), 963-970 (2002).
111. Jin K, Minami M, Lan JQ et al. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc. Natl Acad. Sci. USA 98(8), 4710-4715 (2001).
112. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke. Stroke 38(2 Suppl.), 817-826 (2007).
113. + cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J. Clin. Invest. 114(3), 330-338 (2004).
114. Krupinski J, Kaluza J, Kumar P, Wang M, Kumar S. Prognostic value of blood vessel density in ischaemic stroke. Lancet 342(8873), 742 (1993).
115. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80(1-2), 148-158 (2003).
116. Kurozumi K, Nakamura K, Tamiya T et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol. Ther. 11(1), 96-104 (2005).
117. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol. Cell Physiol. 287(3), C572-C579 (2004).
118. Ripa RS, Wang Y, Jorgensen E et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 27(15), 1785-1792 (2006).
119. Miyagawa S, Sawa Y, Taketani S et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 105(21), 2556-2561 (2002).
120. Chachques JC, Duarte F, Cattadori B et al. Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study. J. Thorac. Cardiovasc. Surg. 128(2), 245-253 (2004).
121. Stevens KR, Rolle MW, Minami E et al. Chemical dimerization of fibroblast growth factor receptor-1 induces myoblast proliferation, increases intracardiac graft size, and reduces ventricular dilation in infarcted hearts. Hum. Gene Ther. 18(5), 401-412 (2007).
122. Kutschka I, Kofidis T, Chen IY et al. Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Circulation 114(1 Suppl.), 1174-1180 (2006).
123. Lee HJ, Kim KS, Park IH, Kim SU. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE 2, E156 (2007).
124. Wei L, Cui L, Snider BJ et al. Transplantation of embryonic stem cells overexpressing Bcl-2 promotes functional recovery after transient cerebral ischemia. Neurobiol. Dis. 19(1-2), 183-193 (2005).
125. Abbott JD, Huang Y, Liu D et al. Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110(21), 3300-3305 (2004).
126. Lunde K, Solheim S, Aakhus S et al. Autologous stem cell transplantation in acute myocardial infarction: the ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand. Cardiovasc. J. 39(3), 150-158 (2005).
127. Hedman M, Hartikainen J, Syvanne M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and instent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107(21), 2677-2683 (2003).
128. Kusumanto YH, van Weel V, Mulder NH et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 17(6), 683-691 (2006).
129. Rajagopalan S, Mohler ER 3rd, Lederman RJ et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108(16), 1933-1938 (2003).
130. Makinen K, Manninen H, Hedman M et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded Phase II study. Mol. Ther. 6(1), 127-133 (2002).
131. Powell RJ, Dormandy J, Simons M, Morishita R, Annex BH. Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc. Med. 9(3), 193-198 (2004).
132. Conte MS, Bandyk DF, Clowes AW et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43(4), 742-751; discussion 751 (2006).